Literature DB >> 17468105

Sequential recruitment of PCAF and BRG1 contributes to myogenin activation in 12-O-tetradecanoylphorbol-13-acetate-induced early differentiation of rhabdomyosarcoma-derived cells.

Zhao-yong Li1, Jun Yang, Xin Gao, Jian-yi Lu, Yi Zhang, Kepeng Wang, Mo-bin Cheng, Ning-hua Wu, Ye Zhang, Zhenguo Wu, Yu-fei Shen.   

Abstract

Myogenin and its upstream regulator MyoD are known to be required for myogenic cell differentiation. Although both of them can be expressed in rhabdomyosarcoma-derived RD cells, the cells are unable to undergo full-scale terminal myogenic differentiation. 12-O-Tetradecanoylphorbol-13-acetate (TPA) has been found to be functional in the induction of RD cell differentiation, whereas its mechanism is not fully understood. By using quantitative real-time-based chromatin immunoprecipitation and real-time reverse transcription-PCR-based promoter activity assays, we examined the activation mechanism of the myogenin gene during TPA-induced differentiation of the RD cells. We have shown that a histone acetyltransferase PCAF and ATPase subunit BRG1 of the SWI/SNF chromatin remodeling complex are sequentially recruited to the promoter of the myogenin gene. Both PCAF and BRG1 are also involved in the activation of the myogenin gene. In addition, we have found that the p38 mitogen-activated protein kinase is required for BRG1 recruitment in TPA-mediated myogenin induction. We propose that there are two distinct activation steps for the induction of myogenin in TPA-induced early differentiation of RD cells: 1) an early step that requires PCAF activity to acetylate core histones and MyoD to initiate myogenin gene expression, and 2) a later step that requires p38-dependent activity of the SWI/SNF remodeling complex to provide an open conformation for the induction of myogenin. Our studies reveal an essential role for epigenetic regulation in TPA-induced differentiation of RD cells and provide potential drug targets for future treatment of the rhabdomyosarcoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17468105     DOI: 10.1074/jbc.M609448200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

Review 1.  Regulating a master regulator: establishing tissue-specific gene expression in skeletal muscle.

Authors:  Arif Aziz; Qi-Cai Liu; F Jeffrey Dilworth
Journal:  Epigenetics       Date:  2010-11-01       Impact factor: 4.528

Review 2.  Nuclear functions of actin.

Authors:  Neus Visa; Piergiorgio Percipalle
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03-17       Impact factor: 10.005

Review 3.  An emerging role for bromodomain-containing proteins in chromatin regulation and transcriptional control of adipogenesis.

Authors:  Gerald V Denis; Barbara S Nikolajczyk; Gavin R Schnitzler
Journal:  FEBS Lett       Date:  2010-05-21       Impact factor: 4.124

4.  Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.

Authors:  Chengyue Zhang; Zheng-Yuan Su; Ling Wang; Limin Shu; Yuqing Yang; Yue Guo; Douglas Pung; Chas Bountra; Ah-Ng Kong
Journal:  Biochem Pharmacol       Date:  2016-08-09       Impact factor: 5.858

5.  Regulation of muscle development by DPF3, a novel histone acetylation and methylation reader of the BAF chromatin remodeling complex.

Authors:  Martin Lange; Bogac Kaynak; Ulrike B Forster; Martje Tönjes; Jenny J Fischer; Christina Grimm; Jenny Schlesinger; Steffen Just; Ilona Dunkel; Tammo Krueger; Siegrun Mebus; Hans Lehrach; Rudi Lurz; Johan Gobom; Wolfgang Rottbauer; Salim Abdelilah-Seyfried; Silke Sperling
Journal:  Genes Dev       Date:  2008-09-01       Impact factor: 11.361

6.  A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.

Authors:  Takenori Shimo; Kana Hosoki; Yusuke Nakatsuji; Toshifumi Yokota; Satoshi Obika
Journal:  J Hum Genet       Date:  2018-01-16       Impact factor: 3.172

7.  TGFBI deficiency predisposes mice to spontaneous tumor development.

Authors:  Ye Zhang; Gengyun Wen; Genze Shao; Cuidong Wang; Chyuansheng Lin; Hongbo Fang; Adayabalam S Balajee; Govind Bhagat; Tom K Hei; Yongliang Zhao
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

8.  The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.

Authors:  Sandra E Ghayad; Ghina Rammal; Omar Sarkis; Hussein Basma; Farah Ghamloush; Assil Fahs; Mia Karam; Mohamad Harajli; Wissam Rabeh; Joe E Mouawad; Hassan Zalzali; Raya Saab
Journal:  Cancer Biol Ther       Date:  2018-10-11       Impact factor: 4.742

9.  Differential effects of AdOx on gene expression in P19 embryonal carcinoma cells.

Authors:  Li Yan; Hai-Yong Zhao; Ye Zhang; Yu-Fei Shen
Journal:  BMC Neurosci       Date:  2012-01-06       Impact factor: 3.288

10.  The histone methyltransferase SUV39H1 suppresses embryonal rhabdomyosarcoma formation in zebrafish.

Authors:  Colleen E Albacker; Narie Y Storer; Erin M Langdon; Anthony Dibiase; Yi Zhou; David M Langenau; Leonard I Zon
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.